Clinical Trial Update: Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial examining idarubicin + cytarabine with lenalidomide for myelodysplastic syndrome and acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-03-28